MEMPHASYS LIMITED. — Capital/Financing Update 2011

Jun 21, 2011

==> picture [196 x 25] intentionally omitted <==

==> picture [196 x 25] intentionally omitted <==

==> picture [196 x 25] intentionally omitted <==

==> picture [196 x 24] intentionally omitted <==

FOR IMMEDIATE RELEASE

1:2 Bonus Options for All Shareholders Timetable

Sydney, Australia 22[nd] June 2011 - NuSep (ASX: NSP) Following the announcement of the 1:2 Bonus 15¢ Share Options on Monday the Board of Nusep wishes to provide the market with a timetable for this pro rata bonus issue.

This will be a bonus pro rata issue of 15¢ Share Options with an expiry date of 31[st] March 2012. The bonus issue will be on a 1 for 2 basis for all ordinary shares held on 12[th] September 2011.

The Board will hold a General Meeting of shareholders on Wednesday 31[st] August 2011 to approve this pro rata 1:2 bonus issue of 15¢ share options with an exercise date of 31[st] March 2012. NuSep will apply to the ASX to have these bonus 15¢ share options listed.

Below is a draft timetable for the 1:2 bonus 15¢ share options.

EVENT	DATE
Shareholders informed of the Offer	Tuesday 14 June 2011
General Meeting to approve the issue of shares underthis Share Purchase Offer, and the Directorsunderwriting of the Share Purchase Offer.	Wednesday 31 August 2011
Bonus Record Date of the Bonus one for two 15¢Share Options	Monday 12 September 2011*
Bonus 15¢ Share Option holding statementsdispatched and normal trading commences	Friday 16 September 2011*

• Subject to shareholder approval at the General Meeting to be held on 31 August 2011

ENDS

For more information please contact:

Contact: Prakash Patel Company Secretary +61 2 8415 7300 prakash.patel@nusep.com

NuSep Holdings Ltd 324 Burns Bay Rd Lane Cove NSW 2066

Postal Address P.O. Box 823

Contact Details Telephone +61 2 8415 7300 Facsimile +61 2 8415 7399

Email info@nusep.com Web www.nusep.com ABN 33 120 047 556

Lane Cove NSW 1595

– 2 –

About NuSep

NuSep (ASX: NSP) is a publicly listed life sciences company that sells products into the global BioSeparations market. NuSep recently acquired BioInquire which developed the ProteoIQ software enabling NuSep to offer a total Proteomics solution from Fraction to Function . The company has offices in both Sydney Australia and Atlanta, USA.

With a 30 year heritage in biological separations, NuSep has forged a world class reputation for its innovative yet simple biological separation techniques including the world’s first IVF sperm separation device. In short NuSep has redefined the BioSeparations market through innovation and simplification.

NuSep’s world renowned research team has developed an extensive portfolio of patented products. In all, NuSep currently manufactures, distributes and sells 55 products to customers in the USA, Europe, Asia and Australia.

NuSep Products:

==> picture [12 x 17] intentionally omitted <==

• Gels – NuSep manufactures and sells precast gels including the innovative nUView Gels, which can be visualised 2 minutes after use.

==> picture [12 x 17] intentionally omitted <==

• Separation Instruments – NuSep has developed two unique biological separation instruments. The ProteomeSep was released in 2009 and can separate biological samples into 8 fractions for use in the proteomic market. The SpermSep separates sperm for fertility treatments such as IVF and is expected to undergoing clinical trials later this year.

==> picture [12 x 17] intentionally omitted <==

• Proteomics Software – NuSep offers the unique ProteoIQ software for the analysis of complex mass spec samples. This software is also designed to identify bio markers.

==> picture [12 x 17] intentionally omitted <==

• Biological Products – NuSep supplies research grade biological products manufactured using its unique separation technologies. These products include human IgG and Albumin.

For more information about NuSep please visit the company’s website www.NuSep.com

About SingaPharm

SingaPharm is a Singapore based biotech company that has developed a disposable procedure for the processing of plasma proteins. SingaPharm is currently a wholly owned subsidiary of NuSep Holdings Limited (ASX: NSP). SingaPharm’s process is based on the Pr eparative I solation by M embrane E lectrophoresis (PrIME) technology developed by NuSep. PrIME provides disposable modular processing that is ‘electronically’ driven membrane fractionation.

This process is flexible and modular compared with the large scale inflexible processing facilities of existing fractionators in US and Europe. The process has increased product yield relative to the existing process with increased product safety. The flexible nature of the PrIME technology also provides SingaPharm with access to plasma volumes that previously did not meet the criteria for larger scale processing facilities. Further, SingaPharm’s process can produce multiple plasma products in hours compared to days, which is required by the current manufacturers.